NEW YORK, NY / ACCESS Newswire / January 22, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn ...

Bearish flow noted in AstraZeneca (AZN) with 1,547 puts trading, or 1.9x expected. Most active are 2/14 weekly 68 puts and Feb-25 70 puts, with ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

AstraZeneca PLC AZN shares inched down 0.11% to £110.40 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.04% to 8,545.13.

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...

A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the ...

NDAQ:AZN) AstraZeneca PLC Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The ...

On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...

Shares of AstraZeneca PLC AZN slid 1.32% to £107.94 Monday, on what proved to be an all-around great trading session for the ...